#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Eosinophilic granulomatosis with polyangiitis Scleroderma associated digital ulcer Diffuse large B-cell lymphoma Chondrosarcoma metastatic Atopic keratoconjunctivitis Intracranial germ cell tumour Chordoma Neuroendocrine carcinoma of the skin Retinal artery occlusion Enteritis Small cell lung cancer recurrent Postprandial hypoglycaemia Hairy cell leukaemia Necrotising enterocolitis neonatal Uveal melanoma More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma metastatic – Trials in Disease Wiskott-Aldrich syndrome – Treatment Rosai-Dorfman syndrome – Treatment Mitochondrial myopathy Angiosarcoma – Basic Information Pituitary-dependent Cushing’s syndrome – Trials in Disease Lymphangioma Rett syndrome – Treatment Hereditary angioedema with C1 esterase inhibitor deficiency – Treatment Von Willebrand’s disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Al8326 Cortisone Esketamine ACARBOSE Mk-0616 Ziltivekimab Dinutuximab Beta Vigabatrin Proguanil Hydrochloride Tislelizumab Incb099280 Egl-001 Nacubactam ACETYLCARNITINE HYDROCHLORIDE Xanomeline Tartrate ALN-961583 Adrc Adezunap Amisulpride Colecalciferol More therapies…

    Learn about Your Condition

    Myotonic dystrophy Polycythaemia vera Thrombosis prophylaxis Marfan's syndrome Obstructive pancreatitis Cholecystitis acute Encephalopathy neonatal Testis cancer Enteritis Gallbladder cancer Vasospasm Embolic stroke Leiomyosarcoma recurrent Spina bifida Peripheral artery stenosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HER2 positive breast cancer

  • Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Neratinib
    Croatia France Italy Spain

  • Study on Trastuzumab Deruxtecan for Patients with Metastatic HER2-Positive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Italy

  • Study on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Trastuzumab Emtansine
    • Atezolizumab
    • Pertuzumab
    Belgium France Poland Portugal Spain

  • Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Trastuzumab Emtansine
    • Atezolizumab
    • Trastuzumab
    Austria Belgium Bulgaria Czechia Denmark France +8

  • Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Tucatinib
    • Anastrozole
    • Exemestane
    France

  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Tucatinib
    • Pertuzumab
    • Trastuzumab
    Austria Belgium Czechia Finland France Germany +6
Previous Page
1 … 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!